Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Sarah M. Osgood"'
Autor:
Jessica Mancuso, Angela C. Doran, Li Di, Bo Feng, Larry M. Tremaine, Jennifer L. Liras, Sarah M. Osgood, Christopher L. Shaffer, Mark A. West
Publikováno v:
Journal of Pharmaceutical Sciences. 107:2225-2235
Four P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) substrates with human cerebrospinal fluid (CSF) concentrations and preclinical neuropharmacokinetics were used to assess in vitro – in vivo extrapolation of brain penetration in
Autor:
Stephanie Fraser, Sarah M. Osgood
Publikováno v:
Bioanalysis. 9:1827-1837
Over the last decade, there has been broad incorporation of translational biomarkers into the early drug development process to predict safety concerns, measure target engagement and monitor disease progression. One goal of translational biomarkers i
Autor:
Sven Akkerman, Christopher L. Shaffer, Sarah M. Osgood, Arjan Blokland, P. Cremers, Jos Prickaerts, N.P. van Goethem, Harry W.M. Steinbusch
Publikováno v:
Neuropharmacology, 97, 233-239. Elsevier Science
In previous studies, we have shown that phosphodiesterase type 5 inhibitors (PDE5-Is) can improve early consolidation of object memory. These conclusions were based on the timing of drug administration relative to the learning trial (i.e. before or a
Publikováno v:
Neuropharmacology. 86:174-180
Ketamine is used preclinically and clinically to study schizophrenia and depression. Accordingly, it is imperative to understand the temporal relationship between the central concentrations and N-methyl-d-aspartate receptor (NMDAR) interactions of bo
Publikováno v:
Journal of Pharmaceutical Sciences. 103:1557-1562
In rats, oxycodone, diphenhydramine, and (4-chloro-5-fluoro-2-(3-methoxy-2-methyl-phenoxy)-benzyl)-methylamine (CE- 157119) undergo net active influx at the blood-brain barrier (BBB) based on significantly greater interstitial fluid compound concentr
Publikováno v:
Cutaneous and Ocular Toxicology. 33:206-211
Selective inhibitors of glycine transporter type 1 (GlyT1) increase synaptic glycine concentrations and are being developed to treat cognitive and negative symptoms of schizophrenia. However, increases in systemic glycine levels have been associated
Autor:
Eric Feyfant, Natasha M. Kablaoui, Heather McInnes, Sarah M. Osgood, Michelle Vanase-Frawley, Ramin Darvari, Angela C. Doran, Kari R. Fonseca, Derek L. Buhl, Mark J. Majchrzak, Meera E. Modi
Publikováno v:
The Journal of Pharmacology and Experimental Therapeutics
Oxytocin (OT) modulates the expression of social and emotional behaviors and consequently has been proposed as a pharmacologic treatment of psychiatric diseases, including autism spectrum disorders and schizophrenia; however, endogenous OT has a shor
Autor:
James Offord, Susan M. Lotarski, Charles Taylor, Sarah M. Osgood, Sean D. Donevan, Julie Poe, Ayman El-Kattan
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 338:615-621
The α(2)δ auxiliary subunits (α(2)δ-1 and α(2)δ-2) of voltage-sensitive calcium channels are thought to be the site of action of pregabalin (Lyrica), a drug that has been shown to be anxiolytic in clinical trials for generalized anxiety disorde
Autor:
Laura McDowell, Sarah M. Osgood, Shari L. DeNinno, Hans Rollema, Chris L. Shaffer, Robert J. Mather, Brenda R. Ellerbrock, Jotham Wadsworth Coe, Theresa Tritto, Rouba Kozak, Jen Sadlier, Raymond S. Hurst, Weldon Horner, Roxanne R Gorczyca, Mary C. MacDougall, F. David Tingley, Mark J. Majchrzak, Lei Zhang, Alka Shrikhande, John A. Lowe, Scot Richard Mente, Karen M. Ward, David E. Johnson
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:4749-4752
We report the synthesis of a series of [3.2.1]azabicyclic biaryl ethers as selective agonists of α3- and α6-containing nicotinic receptors. In particular, compound 17a from this series is a potent α3β4 and α6/4β4 receptor agonist in terms of bo
Autor:
Raymond S. Hurst, Nandini Chaturbhai Patel, Dina McGinnis, Xinjun J. Hou, Mihály Hajós, Dianne K. Bryce, Cheng Chang, Christopher J. O’Donnell, JianHua Liu, William E. Hoffmann, Patricia A. Seymour, Laigao Chen, Renato J. Scialis, Yunjing Wei, Karki Kapil Kumar, R. Scott Obach, Longfei Xie, Jacob Bradley Schwarz, John T. Lazzaro, Kenneth R. Zasadny, Sarah M. Osgood, Christopher J. Schmidt, Christopher L. Shaffer, Jayvardhan Pandit, Susan M. Lotarski, Mark L. Weber
Publikováno v:
Journal of medicinal chemistry. 58(10)
A unique tetrahydrofuran ether class of highly potent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor potentiators has been identified using rational and structure-based drug design. An acyclic lead compound, containing an ether-linked